Nanoparticle hydrogel as well as preparation method and application thereof
By encapsulating antibacterial drugs in the hydrogel, the problems of single function and low strength of existing hydrogel dressings are solved, and multi-path healing and antibacterial effects in diabetic wound healing are achieved, significantly accelerating wounds. Healing process.
Patent Information
- Application Number
- CN202411043104.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-15
AI Technical Summary
Existing hydrogel dressings are single-function, low-strength, and lack controllable release capabilities when treating chronic wounds, making them difficult to continue to play a role in wound healing, especially in the presence of antibacterial and regulatory endogenous factors in diabetic wound healing. limitations.
Develop a nanoparticle hydrogel, using acrylic polymer hydrogel as a carrier, and encapsulate antibacterial drugs such as puerarin in the nanoparticles, achieving the sustained release and antibacterial effects of the drug through porous structure, combining machine stirring shearing method and high pressure The homogenization technology prepares nanoparticles to form regular spherical structures to improve dispersion and stability.
Nanoparticle hydrogels have porous and good swelling properties, achieve long-term effective drug release, provide mechanical strength and antibacterial effects, reduce inflammatory responses, promote angiogenesis and epidermal regeneration, and significantly accelerate the healing of diabetic wounds.
Smart Images

Figure CN118948751A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of biomedical materials, and in particular to a nanoparticle hydrogel and a preparation method and application thereof. Background Art
[0002] Chronic wounds include diabetic foot ulcers, pressure injuries, traumatic ulcers, etc. These wounds are difficult to heal and have a prolonged course of disease. Their treatment and management have brought serious economic burdens to the global healthcare system and also brought great psychological pressure to patients. Among them, the formation of diabetic wounds usually involves the interaction of multiple factors. Chronic inflammation in the wound microenvironment caused by oxidative stress, impaired angiogenesis, increased expression of proinflammatory factors and bacterial infection is considered to be the main reason for the persistence of chronic wounds. At present, the treatments for diabetic wounds mainly include debridement, drug therapy, dressing changes, etc. Traditional dressings such as gauze can play a passive role in wound healing, such as shielding, absorbing exudate and preventing external stimulation and injury, but they also have the limitation of lacking antibacterial or active regulation of endogenous factors. With the continuous development of dressings, hydrogel dressings can provide a moist wound environment, prevent secondary infection, promote autolysis and debridement of necrotic wounds and granulation wounds, and improve wound healing efficiency. It is an ideal wound dressing. However, current hydrogel dressings have problems such as single function, low strength, and lack of controlled release ability, making it difficult for them to continue to play a role in the long-term process of wound healing. Therefore, there is an urgent need to develop a wound dressing that can heal wounds through multiple pathways, has high mechanical strength, and ensures sustained drug release. Summary of the invention
[0003] In order to overcome the problems existing in the above-mentioned prior art, one of the purposes of the present invention is to provide a nanoparticle hydrogel. The second purpose of the present invention is to provide a method for preparing the above-mentioned nanoparticle hydrogel. The third purpose of the present invention is to provide the use of the above-mentioned nanoparticle hydrogel in the preparation of antibacterial drugs. The fourth purpose of the present invention is to provide the use of the above-mentioned nanoparticle hydrogel in the preparation of drugs for wound repair. The fifth purpose of the present invention is to provide a drug for wound repair.
[0004] In order to achieve the above object, the technical solution adopted by the present invention is:
[0005] The first aspect of the present invention provides a nanoparticle hydrogel, comprising an acrylic polymer hydrogel and nanoparticles distributed therein; the acrylic polymer hydrogel is a porous structure; the nanoparticles comprise a carrier material and a drug encapsulated therein, the carrier material is a polylactic acid copolymer, and the drug exists in an amorphous or semi-crystalline form.
[0006] Preferably, the nanoparticles include the following raw materials in parts by weight: 15-25 parts of polylactic acid-glycolic acid copolymer, 35-45 parts of polyvinyl alcohol, 50-70 parts of water-soluble cyclodextrin, 0.5-5 parts of cell-penetrating peptide, and 2-8 parts of drug.
[0007] More preferably, the nanoparticles are made of the following raw materials in parts by weight: 17-23 parts of polylactic acid-glycolic acid copolymer, 37-43 parts of polyvinyl alcohol, 55-65 parts of water-soluble cyclodextrin, 0.5-3 parts of cell-penetrating peptide, and 3-5 parts of drug.
[0008] More preferably, the water-soluble cyclodextrin is one of 2-hydroxypropyl-β-cyclodextrin, sulfobutyl-β-cyclodextrin or a combination thereof.
[0009] Preferably, the medicament comprises a medicament for promoting the healing of chronic wounds.
[0010] More preferably, the drug is puerarin.
[0011] The diabetic chronic wound site has a complex microenvironment, and the healing process is characterized by multiple stages. The nanoparticle hydrogel of the present invention uses puerarin as a therapeutic substance, which can simultaneously combine multiple pathways such as antibacterial, anti-inflammatory, and promoting angiogenesis to accelerate chronic wounds and meet the needs of different stages of wound healing.
[0012] Preferably, the mass ratio of the acrylic polymer hydrogel to the nanoparticles is (1-2.5):1.
[0013] Preferably, the particle size of the nanoparticles is 45 to 350 nm.
[0014] Preferably, the molecular weight of the polylactic acid-glycolic acid copolymer is 10,000-30,000.
[0015] Preferably, the molar ratio of lactic acid monomer (PLA) to glycolic acid monomer (PGA) in the polylactic acid-glycolic acid copolymer is (60-80): (20-40).
[0016] The second aspect of the present invention provides a method for preparing the nanoparticle hydrogel according to the first aspect, comprising the following steps:
[0017] S1, mixing an organic phase including polylactic acid-co-glycolic acid copolymer and a drug with an aqueous phase including polyvinyl alcohol, water-soluble cyclodextrin, and cell-penetrating peptide to obtain a suspension, and crushing the suspension to obtain nanoparticles; mixing an acrylic acid monomer with a cross-linking agent and then heating the mixture to obtain a hydrogel matrix;
[0018] S2, mixing the nanoparticles, the hydrogel matrix and the initiator, and reacting them to obtain the nanoparticle hydrogel.
[0019] Preferably, the solvent of the organic phase is at least one of methanol, ethanol, dichloromethane, chloroform, acetone, isopropanol, tetrahydrofuran, dimethyl sulfoxide, and ethyl acetate.
[0020] More preferably, the solvent of the organic phase is ethanol and dichloromethane, and the volume ratio thereof is (1-3):3.
[0021] Preferably, the volume ratio of the organic phase to the aqueous phase is (1-2):8.
[0022] Preferably, step S1 also includes the following steps: mixing an organic phase including polylactic acid-co-glycolic acid copolymer and the drug with an aqueous phase including polyvinyl alcohol, water-soluble cyclodextrin and cell-penetrating peptide, first performing ultrasonic crushing to volatilize the organic solvent, and then performing high-pressure homogenization to obtain nanoparticles.
[0023] More preferably, the ultrasonic fragmentation time is 10 to 30 minutes.
[0024] More preferably, the process parameters of the ultrasonic crushing are: every 2 seconds of crushing, the interval is 1 to 2 seconds, and the ice bath is used.
[0025] More preferably, the pressure of the high-pressure homogenization is 20-30 kpsi.
[0026] More preferably, the high pressure homogenization is performed 5 to 15 times.
[0027] Preferably, in step S1, the acrylic monomer and the cross-linking agent are mixed in an alcohol aqueous solvent and subjected to hydrothermal treatment at 55 to 65° C. for 50 to 70 min to obtain a hydrogel matrix.
[0028] More preferably, the alcohol aqueous solvent is a 20% to 40% ethanol aqueous solution.
[0029] More preferably, the hydrothermal reaction is carried out under closed conditions.
[0030] Preferably, the cross-linking agent is a small molecule cross-linking agent.
[0031] More preferably, the cross-linking agent is N,N'-methylenebisacrylamide or polyethylene glycol diacrylate.
[0032] Preferably, in step S2, the reaction temperature is 55-65° C., and the reaction time is 1-3 min.
[0033] The third aspect of the present invention provides use of the nanoparticle hydrogel described in the first aspect in the preparation of antibacterial drugs.
[0034] The fourth aspect of the present invention provides use of the nanoparticle hydrogel described in the first aspect in preparing a drug for wound repair.
[0035] The fifth aspect of the present invention provides a medicine for wound repair, comprising the nanoparticle hydrogel described in the first aspect as an active ingredient, and pharmaceutically acceptable excipients.
[0036] Preferably, the drug for wound repair is a drug for promoting the healing of chronic wounds.
[0037] More preferably, the drug for wound repair is a drug for repairing diabetic wounds.
[0038] The beneficial effects of the present invention are:
[0039] The invention provides a nanoparticle hydrogel, comprising an acrylic polymer hydrogel and nanoparticles distributed in the hydrogel, wherein the nanoparticle hydrogel has the following characteristics: (i) the nanoparticle hydrogel is porous, which gives the hydrogel sufficient air permeability, realizes the exchange of nutrients and metabolic wastes, and the drug is loaded in the pores of the acrylic hydrogel in an amorphous or semi-crystalline form, and diffuses and releases the drug through the pores, thereby achieving a long-term effective drug release effect and promoting the healing of chronic wounds; the nanoparticle hydrogel has good swelling properties and can absorb wound exudate in a timely manner; (ii) the nanoparticle hydrogel is transparent in appearance, which is convenient for observing the wound healing at any time; the nanoparticle hydrogel is soft and tough, can provide a certain mechanical strength to adapt to the joint movement of the drug administration site, can fit the wound, and create a closed and sterile environment for wound healing.
[0040] Specifically, the present invention also has the following advantages:
[0041] 1. The nanoparticles of the nanoparticle hydrogel of the present invention have a strong interaction with the polyacrylic acid side chain groups, the nanoparticles are more tightly bound, and their integrity is well maintained. The structure of the hydrogel prevents the sudden release of the nanoparticles. The diffusion of the drug must overcome the double barriers of the interaction between the nanoparticles and the hydrogel and the degradation of PLGA to avoid the sudden release of the drug and ensure the sustained release of the drug to promote the healing of chronic wounds.
[0042] 2. The nanoparticle preparation method of the present invention combines a machine stirring shearing method and a high-pressure homogenization technology. The prepared nanoparticles have a regular spherical structure, a small particle size and a narrow particle size distribution, good dispersibility, and no adhesion between particles. In the preparation method of the nanoparticle hydrogel, a copolymerization method is adopted to load the nanoparticles in the hydrogel. The preparation method is simple and easy for industrial production.
[0043] 3. The nanoparticle hydrogel of the present invention has outstanding antibacterial effect and has great potential in the treatment of chronic wounds; the nanoparticle hydrogel applied to diabetic wounds can accelerate wound healing by reducing inflammatory response at the wound site, promoting angiogenesis, promoting epidermal regeneration and collagen deposition. BRIEF DESCRIPTION OF THE DRAWINGS
[0044] Figure 1 Schematic diagram of the preparation process of nanoparticle hydrogel (Pue-NPs Gel);
[0045] Figure 2 This is the appearance of puerarin nanoparticles (Pue NPs) solution;
[0046] Figure 3 is the particle size distribution diagram of Pue NPs solution;
[0047] Figure 4 is the potential diagram of Pue NPs solution;
[0048] Figure 5 is the transmission electron microscopy image of Pue NPs solution;
[0049] Figure 6 This is the appearance picture of Pue-NPs Gel;
[0050] Figure 7 is the mechanical properties diagram of Pue-NPs Gel;
[0051] Figure 8 is the scanning electron microscopy image of Pue-NPs Gel;
[0052] Fig. 9 This is the water absorption and swelling diagram of Pue-NPs Gel;
[0053] Fig.10 is the stress-strain diagram of Pue-NPs Gel;
[0054] Fig.11 is the infrared spectrum of Pue-NPs Gel;
[0055] Fig.12 is the differential scanning calorimetry graph of Pue-NPs Gel;
[0056] Fig.13 is the X-ray diffraction pattern of Pue-NPs Gel;
[0057] Fig.14 This is the in vitro release behavior diagram of Pue in Pue-NPs Gel;
[0058] Fig.15 is the antibacterial activity diagram of Pue-NPs Gel;
[0059] Fig.16 This is the wound image of Pue-NPs Gel in treating diabetic mouse wound model;
[0060] Fig.17This is a statistical diagram of the wound area in the diabetic mouse wound model treated with Pue-NPs Gel;
[0061] Fig.18 HE staining of mouse wound tissue sections after Pue-NPs Gel treatment for 7 and 14 days;
[0062] Fig.19 Masson staining of mouse wound tissue sections after Pue-NPs Gel treatment for 7 and 14 days;
[0063] Fig. 20 CD31 staining image of the histological results of Pue-NPs Gel in treating diabetic mouse wound model;
[0064] Fig.21 Ki67 staining image of the histological results of Pue-NPs Gel in treating diabetic mouse wound model;
[0065] Fig. 22 The results of the expression of inflammatory factors by Pue-NPs Gel in the treatment of diabetic mouse wound model; (A) is the quantitative analysis of the inflammatory factor IL-1β, and (B) is the quantitative analysis of the inflammatory factor TNF-α. DETAILED DESCRIPTION
[0066] The present invention is further described in detail below through specific examples. The raw materials used in the following examples, unless otherwise specified, can be obtained from conventional commercial sources or prepared and separated by simple synthesis; the processes used, unless otherwise specified, are conventional processes in the art.
[0067] Example 1
[0068] This embodiment provides a method for preparing nanoparticle hydrogel. The schematic diagram of the preparation process is shown in Figure 1 As shown, the specific process is:
[0069] (1) Preparation of nanoparticles by emulsification solvent evaporation method
[0070] 1g polyvinyl alcohol (PVA, 0588 low viscosity type), 1.5g 2-hydroxypropyl-β-cyclodextrin (2-HP-β-CD) and 40mg cell-penetrating peptide (CPP, Penetratin RK-16) were added to 100mL distilled water and thoroughly dissolved as the aqueous phase; 12mL anhydrous ethanol and 18mL dichloromethane were prepared and mixed evenly as the organic phase; 40mg puerarin (Pue) and 200mg polylactic acid-glycolic acid copolymer (PLGA, MW=20000, LA / GA=75 / 25) were weighed and added to 5mL of the organic phase; the organic phase was slowly injected into 40mL of the aqueous phase using a syringe to obtain a suspension;
[0071] The suspension was worked in a cell disruptor sonicator for 2 10-min cycles with the working parameters of 200 W, 2-s working interval and 2-s ice bath; the sample was then placed in a fume hood and magnetically stirred (560 rpm, 16 h), and then the volume was fixed to 50 mL with distilled water; the suspension was treated 10 times with a microfluidizer at 25 kpsi and 15° C. to obtain a nanoparticle solution, which was filtered to obtain puerarin nanoparticles (Pue NPs).
[0072] (2) Preparation of nanoparticle hydrogels by copolymerization
[0073] 0.015 g of crosslinking agent N,N'-methylenebisacrylamide (BIS) was dissolved in 6 g of 30% ethanol aqueous solution, 3 g of monomer acrylic acid (AA) was added, the mixture was sealed with a film, and heated in a water bath at 60°C for 1 h;
[0074] 7 g of gel matrix was taken out, cooled to room temperature, and then 3 g of puerarin nanoparticles and 0.3 g of initiator ammonium persulfate (APS) were added. After complete dissolution, they were heated in a 60°C water bath and reacted for 2 min to obtain puerarin-loaded nanoparticle hydrogel (Pue-NPsGel).
[0075] Material characterization
[0076] The appearance of the puerarin nanoparticles (Pue NPs) solution prepared in step (1) was observed, and the results were as follows: Figure 2 As shown, the Pue NPs solution exhibits light blue opalescence and has a Tyndall effect.
[0077] The particle size distribution of Pue NPs was tested and the results were as follows: Figure 3As shown, the left ordinate is the differential distribution (Differential Intensity), the right ordinate is the cumulative distribution (Cumulative Intensity), and the horizontal axis is the particle size. The average particle size of Pue NPs is (134.57±1.42) nm, and the PDI value is (0.112±0.008), indicating that PueNPs have a smaller particle size and a narrow particle size distribution.
[0078] The potential of Pue NPs was tested and the results were as follows: Figure 4 As shown, Pue NPs are positively charged with a Zeta potential of (2.14±0.78) mV.
[0079] Pue NPs were observed under transmission electron microscopy. Figure 5 As shown, Pue NPs have a regular spherical structure, good dispersion, and no adhesion between particles;
[0080] The nanoparticle hydrogel (Pue-NPs Gel) prepared in step (2) was observed. Figure 6 As shown, the composite hydrogel is colorless and transparent, round in shape, with a smooth, flat and soft surface, allowing the wound healing process to be observed at any time.
[0081] The mechanical properties of Pue-NPs Gel were investigated. Figure 7 As shown, Pue-NPs Gel exhibits excellent mechanical properties on the surface of finger skin. The hydrogel adhered to the finger can adapt well to the movement of the finger, can be stretched, bent and twisted without deformation, and can be easily peeled off from the finger to ensure that there is no residue on the finger.
[0082] The internal structure of Pue-NPs Gel was observed under a scanning electron microscope. Figure 8 As shown, Pue-NPs Gel is highly porous, which gives the hydrogel sufficient gas permeability.
[0083] The water absorption performance of Pue-NPs Gel was investigated. Fig. 9 As shown in the figure, the swelling ratio increased sharply in the first 2 hours, and basically reached swelling equilibrium after 72 hours, with a swelling ratio of 917%, indicating that Pue-NPsGel has good water absorption.
[0084] Fig.10This is the stress-strain diagram of the Pue-NPs Gel prepared in this example. The maximum strain of the Pue-NPs Gel is about 350%, which is much larger than the strain that the human body can withstand (45-80%). The tensile strength is 18 kPa, which is within the elastic modulus range of human skin tissue (1-100 kPa).
[0085] Infrared spectroscopy, differential scanning calorimetry and X-ray diffraction were used to determine the existence forms of puerarin and carrier materials in the Pue-NPsGel prepared in Example 1.
[0086] Fig.11 This is the infrared spectrum of the Pue-NPs Gel prepared in Example 1. The characteristic peak of Pue is 1609 cm -1 (benzene ring C=C stretching), 1621 cm -1 (aromatic conjugated carbonyl stretching), 3397 cm -1 (-OH stretching). However, after being encapsulated by nanoparticles or hydrogels, the characteristic peak of Pue shifts or disappears, which may be caused by hydrogen bonds or other non-covalent interactions with the excipients, forming a co-amorphous peak.
[0087] Fig.12 This is the differential scanning calorimetry diagram of Pue-NPs Gel prepared in Example 1. Pue crystals are monohydrates, the broad peak at 135.1°C is its dehydration endothermic peak, and the endothermic peak at 216.4°C is the melting peak. In nanoparticles or hydrogels, the melting peak of Pue disappears, and Pue in the system may exist in the carrier in an amorphous or semi-crystalline form.
[0088] Fig.13 This is the X-ray diffraction pattern of Pue-NPs Gel prepared in Example 1. The XRD spectrum shows that Pue has many diffraction peaks within a certain diffraction angle range (2θ), which are 13.91°, 18.90°, 19.69°, 21.16° and 23.41°, respectively, indicating its crystallinity. The intensity of the corresponding peaks in the XRD spectrum of the puerarin preparation is significantly reduced. Therefore, it can be found that the encapsulated Pue may exist in the form of molecular dispersion or in an amorphous state in different systems. The drug has been wrapped or adsorbed by the carrier and is no longer a simple physical mixture, that is, a new phase is formed.
[0089] Experimental analysis
[0090] 1. Sustained release effect test
[0091] The in vitro release behavior of the Pue-NPs Gel prepared in this example was studied using the dialysis bag method. Fig.14As shown in the figure, the cumulative release of NPs in the first hour was 57.91%. The burst release in the first hour may be related to the fact that some free drugs were adsorbed on the surface of the nanoparticle carrier, and their structure was relaxed after contact with the release medium, and they were quickly distributed in the release medium. As PLGA degraded, the drug was slowly released in the next 8 hours, with a cumulative release rate of 91.13%. The side effects caused by the initial burst release of NPs will affect the stability and safety of drug treatment. In Pue-NPs Gel, since the surface of the nanoparticles modified with the transmembrane peptide contains abundant amine groups, the N atoms on the surface of the nanoparticles form hydrogen bonds with the H atoms on the side chains of polyacrylic acid. The interaction between the nanoparticles and the hydrogel makes the two more tightly bound, and the integrity of the nanoparticles is well maintained. The release curve shows that the structure of the hydrogel prevents the burst release of the nanoparticles, and the diffusion of the drug must overcome the double barriers of the interaction between the nanoparticles and the hydrogel and the degradation of PLGA.
[0092] 2. Antibacterial test
[0093] Escherichia coli (Gram-negative bacteria) was selected and the antibacterial activity of Pue-NPs Gel was evaluated by scanning electron microscopy.
[0094] The morphological changes of Escherichia coli after incubation with Pue-NPs Gel for 4 h were observed under scanning electron microscopy. Fig.15 As shown, the surface of E. coli treated with PBS was intact, but after co-incubation with Pue-NPs Gel, the E. coli cells were severely ruptured and the bacterial morphology was incomplete.
[0095] 3. Test on promoting healing effect
[0096] The streptozotocin-induced diabetic mouse model was established to evaluate the healing performance of Pue-NPs Gel in full-thickness skin defects in diabetic mice. The wounds in the disease model group were wiped with normal saline, the wounds in the blank control group were applied with non-drug-loaded polyacrylic acid hydrogel (PAA-Gel), and the wounds in the drug-treated group were applied with Pue-NPs Gel. The treatment was once every 3 days for 14 consecutive days. The wounds were examined and photographed on days 0, 3, 7, 10, and 14 after the wound occurred. The wound area was calculated using ImageJ software, and samples were taken on days 7 and 14 for pathological and histological analysis and determination of inflammatory factor levels.
[0097] Fig.16The effect diagram of Pue-NPs Gel prepared in Example 1 on promoting wound healing in the diabetic mouse wound model. Macroscopically, the wound areas of the three groups gradually became smaller, and at each specific time point, the Pue-NPs Gel group showed faster healing than other groups. After 7 days of observation, the scabs in the Pue-NPs Gel group fell off and the hair around the wound began to grow. The new granulation tissue on the wound was pink and rosy. At this time, the disease model group still had some suppuration, and the granulation tissue matured slowly.
[0098] Fig.17 The wound area statistics of Pue-NPs Gel prepared in Example 1 in the diabetic mouse wound model, wound closure rate is the wound closure rate. On the 7th day, the Pue-NPs Gel group achieved 81.54% wound contraction, and the healing rates of the Model group and the PAA-Gel group were only 65.19% and 73.58%, respectively. By the 14th day, the wound of Pue-NPs Gel was almost completely healed, and the Model group still showed 15.83% of the wound area. The above results show that Pue-NPs Gel can improve the healing efficiency of chronic diabetic wounds.
[0099] Fig.18 and Fig.19 Pathological evaluation diagram of the Pue-NPs Gel prepared in Example 1 in promoting wound healing in a diabetic mouse wound model, specifically HE staining diagram of mouse wound tissue sections after 7 and 14 days of treatment ( Fig.18 ) and Masson staining ( Fig.19 ). HE staining results showed that after 7 days of administration, obvious inflammatory infiltration was observed in the Model group, indicating that there was a severe inflammatory response in the area. In contrast, Pue-NPs Gel showed more tightly packed fibroblasts, accompanied by more capillaries (marked by arrows), providing sufficient nutrition for wound healing. The epidermis of the Pue-NPs Gel group was basically complete, no epithelialization was observed in the Model group, and the PAA-Gel group had a discontinuous epidermis. After 14 days of administration, the number of inflammatory cells in each group decreased, the capillaries in the Pue-NPs Gel group decreased, and more skin appendages appeared (such as hair follicles, shown by arrows), which was very similar to the state of healthy skin tissue. Masson staining results showed that on the 7th day, the Model group and the PAA-Gel group showed accumulation of muscle fibers, as well as relatively low collagen content, and the distribution of collagen fibers was sparse and random. After 14 days of administration, the collagen contents of the groups were 65.50%, 74.46%, and 82.24%, respectively, and the wounds treated with Pue-NPs Gel showed the most compact and evenly distributed collagen fibers among all groups, indicating improved ECM and tissue remodeling.
[0100] Fig. 20 and Fig.21 This is a histological evaluation diagram of the Pue-NPs Gel prepared in Example 1 promoting wound healing in a diabetic mouse wound model, wherein Fig. 20 For CD31 staining, Fig. 22 Staining for Ki67. On the 7th day, only a small number of Ki67-positive cells were observed in the Model group, while extensive cell proliferation was observed in the Pue-NPs Gel group. On the 14th day, a large amount of yellow or brown substances accumulated, and the wound site showed the highest Ki67-positive cell rate, which was significantly different from the disease model group. The above results indicate that Pue-NPs Gel effectively accelerates wound repair by promoting angiogenesis and cell proliferation.
[0101] Fig. 22 This is a diagram showing the expression of inflammatory factors in the wound healing of diabetic mice by Pue-NPs Gel prepared in Example 1. On the 7th day, IL-1β was released from the lesion area in large quantities (112 pg·mL -1 ), but it was significantly reduced after Pue-NPs Gel treatment (70 pg·mL -1 Similar results were also found for TNF-α (151 pg·mL in the Model group). -1 , Pue-NPs Gel group 103pg·mL -1 ). In the subsequent treatment, IL-1β and TNF-α in each group decreased over time. In conclusion, Pue-NPs Gel can reduce the inflammatory response and promote angiogenesis by downregulating the expression of IL-1β and TNF-α and upregulating the expression of CD31 and Ki67, thereby accelerating wound healing.
[0102] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications made without departing from the spirit and principles of the present invention shall be equivalent replacement methods and shall be included in the protection scope of the present invention.
Claims
1. A nanoparticle hydrogel, It is characterized in that The invention comprises an acrylic polymer hydrogel and nanoparticles distributed therein; the acrylic polymer hydrogel is a porous structure; the nanoparticles comprise a carrier material and a drug encapsulated therein, the carrier material is a polylactic acid copolymer, and the drug exists in an amorphous or semi-crystalline form.
2. The nanoparticle hydrogel according to claim 1, It is characterized in that The nanoparticles include the following raw materials in parts by weight: 15-25 parts of polylactic acid-glycolic acid copolymer, 35-45 parts of polyvinyl alcohol, 50-70 parts of water-soluble cyclodextrin, 0.5-5 parts of cell-penetrating peptide, and 2-8 parts of drugs.
3. The nanoparticle hydrogel according to claim 1, It is characterized in that The mass ratio of the acrylic polymer hydrogel to the nanoparticles is (1-2.5):1; And / or, the particle size of the nanoparticles is 45 to 350 nm.
4. A method for preparing the nanoparticle hydrogel according to any one of claims 1 to 3, It is characterized in that The steps include: S1, mixing an organic phase including polylactic acid-co-glycolic acid copolymer and a drug with an aqueous phase including polyvinyl alcohol, water-soluble cyclodextrin, and cell-penetrating peptide to obtain a suspension, crushing and homogenizing the suspension to obtain nanoparticles; mixing an acrylic acid monomer with a cross-linking agent and then heating the mixture to obtain a hydrogel matrix; S2, mixing the nanoparticles, the hydrogel matrix and the initiator, and reacting them to obtain the nanoparticle hydrogel.
5. The method for preparing the nanoparticle hydrogel according to claim 4, It is characterized in that In step S1, the acrylic monomer and the cross-linking agent are mixed in an alcohol aqueous solvent and subjected to hydrothermal treatment at 55-65° C. for 50-70 min to obtain a hydrogel matrix.
6. The method for preparing the nanoparticle hydrogel according to claim 4, It is characterized in that In step S2, the reaction temperature is 55-65° C., and the reaction time is 1-3 min.
7. Use of the nanoparticle hydrogel according to any one of claims 1 to 3 in the preparation of antibacterial drugs.
8. Use of the nanoparticle hydrogel according to any one of claims 1 to 3 in the preparation of a medicament for wound repair.
9. A medicine for wound repair, It is characterized in that The invention comprises an active ingredient and a pharmaceutically acceptable excipient, wherein the active ingredient is the nanoparticle hydrogel according to any one of claims 1 to 3.
10. The medicament for wound repair according to claim 9, It is characterized in that The medicine for wound repair is a medicine for promoting the healing of chronic wounds.
Citation Information
Patent Citations
Antioxidant hydrogel for promoting wound healing as well as preparation method and application of antioxidant hydrogel
CN108744025A
Drug sustained-release wound dressing based on natural hydrogel and preparation method of drug sustained-release wound dressing
CN117838915A
Cited By
Glycyrrhizic acid astragaloside composite hydrogel and application thereof
CN121891289A
